Janney Montgomery Scott LLC Buys 1,540 Shares of Charles River Laboratories Intl. Inc (CRL)

Share on StockTwits

Janney Montgomery Scott LLC grew its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 9.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,521 shares of the medical research company’s stock after purchasing an additional 1,540 shares during the period. Janney Montgomery Scott LLC’s holdings in Charles River Laboratories Intl. were worth $2,690,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in CRL. JPMorgan Chase & Co. boosted its position in Charles River Laboratories Intl. by 45.5% in the third quarter. JPMorgan Chase & Co. now owns 126,896 shares of the medical research company’s stock valued at $17,072,000 after buying an additional 39,685 shares in the last quarter. Morgan Stanley boosted its position in Charles River Laboratories Intl. by 206.0% in the third quarter. Morgan Stanley now owns 187,838 shares of the medical research company’s stock valued at $25,272,000 after buying an additional 126,456 shares in the last quarter. CX Institutional acquired a new stake in Charles River Laboratories Intl. in the fourth quarter valued at approximately $351,000. Cardinal Capital Management boosted its position in Charles River Laboratories Intl. by 1.6% in the fourth quarter. Cardinal Capital Management now owns 8,459 shares of the medical research company’s stock valued at $957,000 after buying an additional 137 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in Charles River Laboratories Intl. in the fourth quarter valued at approximately $805,000. Institutional investors and hedge funds own 94.56% of the company’s stock.

In other news, EVP Joseph W. Laplume sold 5,522 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $137.61, for a total transaction of $759,882.42. Following the completion of the transaction, the executive vice president now owns 16,325 shares of the company’s stock, valued at $2,246,483.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David Ross Smith sold 4,000 shares of the firm’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $145.43, for a total transaction of $581,720.00. Following the transaction, the chief financial officer now directly owns 24,262 shares of the company’s stock, valued at approximately $3,528,422.66. The disclosure for this sale can be found here. Insiders have sold 32,428 shares of company stock valued at $4,597,693 in the last ninety days. Insiders own 1.80% of the company’s stock.

A number of brokerages have weighed in on CRL. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “sell” rating to a “hold” rating in a research report on Thursday. Wolfe Research began coverage on shares of Charles River Laboratories Intl. in a research report on Tuesday, April 2nd. They issued a “market perform” rating on the stock. Barclays raised their target price on shares of Charles River Laboratories Intl. from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, March 18th. KeyCorp raised their target price on shares of Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a research report on Monday, March 11th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $162.00 target price on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $145.64.

CRL stock opened at $136.54 on Friday. The firm has a market cap of $6.66 billion, a PE ratio of 22.64, a price-to-earnings-growth ratio of 1.76 and a beta of 0.99. Charles River Laboratories Intl. Inc has a 52-week low of $102.96 and a 52-week high of $149.07. The company has a quick ratio of 1.38, a current ratio of 1.63 and a debt-to-equity ratio of 1.10.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Tuesday, May 7th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.38 by $0.02. The firm had revenue of $604.57 million during the quarter, compared to the consensus estimate of $587.65 million. Charles River Laboratories Intl. had a net margin of 9.63% and a return on equity of 23.03%. The company’s revenue for the quarter was up 22.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.29 earnings per share. On average, research analysts predict that Charles River Laboratories Intl. Inc will post 6.47 EPS for the current year.

WARNING: “Janney Montgomery Scott LLC Buys 1,540 Shares of Charles River Laboratories Intl. Inc (CRL)” was first posted by Macon Daily and is owned by of Macon Daily. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://macondaily.com/2019/05/11/janney-montgomery-scott-llc-buys-1540-shares-of-charles-river-laboratories-intl-inc-crl.html.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.